Article
Daily Medication Pearl: Ixekizumab (Taltz)
Author(s):
Ixekizumab (Taltz) is indicated for the treatment of conditions such as plaque psoriasis, psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial spondyloarthritis.
Medication Pearl of the Day: Ixekizumab (Taltz)
Indication: Ixekizumab (Taltz) is a humanized interleukin-17A antagonist indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, as well as active psoriatic arthritis, active ankylosing spondylitis, and active non-radiographic axial spondyloarthritis with objective signs of inflammation.
Insight:
Dosing: Recommended dose is 160 mg (two 80 mg injections) at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.
Dosage forms: Injection 80 mg/mL solution in a single-dose prefilled autoinjector.
Adverse events: Most common (≥1%) adverse reactions associated with ixekizumab treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections.
Mechanism of action: Ixekizumab is a humanized immunoglobulin G4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.
Manufacturer: Eli Lilly
Sources:
